A sexual health clinic in London has tested drug levels in users of generic PrEP medication bought online and found the drugs are genuine and effective.
nam/aidsmap, 29 January 2016
Several large sexual health clinics in London and Brighton have responded to the growing numbers of people importing PrEP medications from overseas by offering free safety monitoring to PrEP users. This is in a context of increasing frustration with the slowness of the official NHS process to approve PrEP – no decision will be made until June at the earliest.
NAM , 02 December 2015
The results from the Ipergay study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine (NEJM) on 1 December, World AIDS Day. The journal-published results are little changed from those presented at the CROI conference last February by principal investigator Jean-Michel Molina, but the researchers make a number of additional comments and are notably cautious about not over-interpreting a study that only had 400 participants – very small for a prevention study – and an average of nine months’ follow-up.
It is the first, and so far only. randomised study to show that PrEP can be just as effective if it is given as an intermittent regimen that users only take when anticipating sex, rather than daily.
Read more here
AIDSMEDS, August 17, 2015
People with hepatitis B virus (HBV) can safely take Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP), as it does not lead to liver inflammation “flares” or other health problems when it is used or discontinued.
Read more here